By Jaime Llinares Taboada

 

The U.K. Competition and Markets Authority said Friday that it has decided it won't refer Thermo Fisher Scientific Inc.'s planned $17.4 billion acquisition of pharmaceutical-testing company PPD Inc. to a phase 2 investigation.

The regulator had announced a probe into the deal in October, to see if it would lead to a lessening of competition.

 

Write to Jaime Llinares Taboada at jaime.llinares@wsj.com; @JaimeLlinaresT

 

(END) Dow Jones Newswires

December 03, 2021 02:32 ET (07:32 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
PPD (NASDAQ:PPD)
Historical Stock Chart
From Dec 2021 to Jan 2022 Click Here for more PPD Charts.
PPD (NASDAQ:PPD)
Historical Stock Chart
From Jan 2021 to Jan 2022 Click Here for more PPD Charts.